The Forkhead box M1 transcription factor (FoxM1) is essential for DNA replication and mitosis, and has important role in cell proliferation and apoptosis. To assess the role of FoxM1 in chemoresistance, we investigated FoxM1 protein expression and the correlation between FoxM1 expression, sensitivity to cisplatin-based therapy, and the survival of non-small cell lung cancer (NSCLC) patients. We generated a cisplatin-resistant lung cancer cell line (A549/CDDP) that showed elevated expression levels of FoxM1 protein and mRNA relative to those of the parental A549 cells. We investigated the effect of the knockdown or overexpression of FoxM1 on the sensitivity to cisplatin and the possible signaling transduction pathways in these cells. Our results revealed that the positive expression rate of FoxM1 in NSCLC was associated with chemosensitivity to cisplatin and a poor prognosis. When the expression of FoxM1 was inhibited by RNA interference, the sensitivity to cisplatin was enhanced. Inversely, in FoxM1-overexpressing cell models, we observed a reduced sensitivity to cisplatin. Moreover, we showed that the downregulation of FoxM1 enhanced cisplatin-induced A549/CDDP cell apoptosis through the activation of the c-Jun NH2-terminal kinase (JNK)/mitochondrial pathway. These results suggest that FoxM1 plays a critical role in chemoresistance to cisplatin and that FoxM1 depletion may be a promising approach to lung cancer therapy.
Lung cancer is one of the most common malignancies worldwide, and is the leading cause of cancer-related death [1] . Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80-85% of all lung cancer cases [2] . Approximately 70% of NSCLCs are in an advanced stage at the time of diagnosis [3] and, consequently, the 5-year survival across stages is only 15%. Systemic chemotherapy is still the main life-prolonging and palliative treatment in advanced NSCLC, and cis-diamminedichloroplatinum (CDDP, cisplatin) is the backbone of first-line chemotherapy doublets. However, both acquired and intrinsic resistances remain a major hurdle that has limited the treatment success. The mechanisms of cisplatin resistance involve multiple pathways, including the evasion of apoptotic pathways, a bypass of the replication checkpoint, increased cell proliferation, and increased DNA damage repair [4, 5] , which are not fully understood. Therefore, further elucidating the biological mechanisms of cisplatin resistance and the key molecules and pathways that regulate this resistance is necessary to overcome treatment plateaus in NSCLC.
Forkhead box M1 (FoxM1), which belongs to the Forkhead transcription factor family, is essential for DNA replication and mitosis, and has important roles in cell proliferation and apoptosis [6, 7] . The expression of FoxM1 is enhanced in the G1/S and G2/M phases and can mediate cells in the S and M phases [8, 9] . The knockout of FoxM1 causes failure to enter the S phase and improper M phase completion in cells, which leads to centrosome amplification and mitotic catastrophe [10, 11] . The upregulation of FoxM1 expression is closely associated with the occurrence, development, and prognosis of various human cancers such as pancreatic cancer and lung cancer [12] [13] [14] . Furthermore, FoxM1 expression level correlates positively with tumor size, clinical stage, metastasis, and survival in breast cancer and colon carcinoma [15, 16] .
In addition to being a cell cycle transcription factor, recent studies have confirmed that FoxM1 is involved in DNA damage and apoptosis pathways, which suggests that FoxM1 plays a role in multidrug resistance [17] [18] [19] [20] . FoxM1 stimulates the transcription of the X-ray repair cross-complementing group 1 (XRCC1) [21] and the breast cancer-associated gene 2 (BRCA2), which are involved in the homologous recombination repair of DNA double-strand breaks [22] [23] [24] . FoxM1-deficient(-/-) mouse embryonic fibroblasts (MEFs) and osteosarcoma U2OS cells exhibit DNA breaks, increased transcriptional activation of the p53 tumor suppressor, and increased mRNA and protein levels of the p53 downstream target p21 cip1 [25] . Furthermore, an increased expression of FoxM1 and its downstream targets, which are involved in DNA repair and apoptosis, has been observed in cisplatin-resistant breast cancer cell line (MCF-7-CIS R ). Silencing FoxM1 expression caused breast cancer cells to become more sensitive to doxorubicin by regulating DNA repair genes [26] . In addition, FoxM1 mediates the resistance to herceptin and paclitaxel by regulating the tubulin-destabilizing protein stathmin in breast cancer cells [27] . Attenuated FoxM1 expression restored the sensitivity to gefitinib in lung cancer cells by inhibiting proliferation and inducing apoptosis [28] . These results suggest a novel role for FoxM1 in the transcriptional response to DNA damage signaling and the induction of apoptosis, and a potential target for reversing chemoresistance.
In our study, we first investigated FoxM1 protein expression levels and the correlation between FoxM1 expression, sensitivity to cisplatin-based therapy, and the survival of NSCLC patients. Then, we investigated the effect of FoxM1 knockdown or overexpression on human NSCLC cell sensitivity to cisplatin and the possible mechanism for this sensitivity.
Patients and methods
Patients and clinical specimens. In this study, we examined samples from 50 patients with histopathologically confirmed primary NSCLC without radical surgery at our hospital from 2004-2008. All patients were untreated. The first-line treatment was a cisplatin-based regimen for at least 2 cycles. The efficacy of chemotherapy was evaluated by spiral computed tomography (CT) after 2-4 cycles. All patients clinical and pathological data were integrated.
Immunohistochemical analysis. FoxM1 protein accumulation was examined by immunohistochemical (IHC) staining. Sections from paraffin-embedded tumors were incubated with a sheep anti-human FoxM1 monoclonal antibody (R&D Systems; Littleton, CO, USA) at a 1:2000 dilution for 3 h, followed by washing with phosphate-buffered saline (PBS) and incubation with a goat anti-sheep secondary antibody (Thermo Fisher Scientific, Inc.; Rockford, IL, USA). Antigen-antibody complexes were visualized by incubation with 3΄,3-diaminobenzidine (DAB) substrate and counterstained with diluted Harris hematoxylin. A negative control was run simultaneously using the primary antibody. Normal human lung tissue was used as a positive control.
Immunohistochemical staining of FoxM1 in the tissue was scored by pathologists blinded to the clinicopathological parameters, by applying a modification of the semi-quantitative immunoreactivity score (IRS) in the training cohort, as reported elsewhere. Category A documented the intensity of immunostaining as 0-3 (0, no immunostaining; 1, weak immunostaining; 2, moderate immunostaining; 3, strong immunostaining). Category B documented the percentage of immunoreactive cells as 0 (<1%), 1 (1-10%), 2 (11-50%), and 4 (51-100%). Multiplication of category A and B resulted in an IRS ranging from 0 to 12 for each tumor. A resulting score of >4 was considered positive, whereas a score of 0-3 was considered negative.
Cell culture and chemotherapeutic agents. A549 (human lung adenocarcinoma) cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and grown in RPMI 1640 (HyClone; Logan, UT, USA), which was supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 g/mL streptomycin in a 37°C CO 2 incubator. The cells were selected by stepwise exposure to increasing CDDP concentrations up to 5 Ag/mL L. The cells were then maintained for at least 6 months in medium that contained 5 Ag/mL CDDP. The CDDP-resistant cells (A549/CDDP) were cultured without CDDP for 2 weeks before analysis. CDDP was purchased from Sigma (St Louis, MO, USA), dissolved in dimethyl sulfoxide and stored at −20°C.
Cytotoxicity analysis. The cells were plated in 96-well plates and incubated for an additional 24 h. The cells were treated with various concentrations (0, 5, 10, 20, 40, and 80 μmol/L) of cisplatin. After 48 h of incubation, 10 μL of Cell Counting Kit-8 (CCK-8) was added, and the culture was continued for 3 h in a humidified atmosphere that contained 5% CO 2 . Absorbance was measured at 450 nm using a microplate reader (Bio-Tech; VT, USA). The relative drug resistance fold-changes were determined according to the 50% inhibitory concentration (IC50).
Real-time quantitative polymerase chain reaction (PCR). For real-time PCR, total RNA was extracted from tissues and sorted cells using the RNeasy Mini Kit (Qiagen; Hilden, Germany). A complementary DNA synthesis was performed using SuperScript Reverse Transcriptase (RT) II (Invitrogen; Carlsbad, CA, USA) and a mixture of oligo (dT). SYBR Green-based real-time PCR was conducted with FastStart Universal SYBR Green (ROX) reagents and an ABI PRISM 7300 Genetic Analyzer (Applied Biosystems; Foster City, CA, USA). The cycling program was 95°C for 20 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Each sample was assayed in triplicate and the results were normalized to the level of the ribosomal protein L19 RNA. The forward and reverse primers were as follows:
Western blotting. The cells were collected and washed with PBS before incubation in radioimmunoprecipitation assay buffer that contained 1% Nonidet P-40, 50 mM Tris-HCl (pH 7.4), 1 mM ethylenediaminetetraacetic acid, 150 mM NaCl, and the addition of a complete protease inhibitor mixture. The cells were lysed on ice for 20 min and spun down to remove cell debris. The protein concentration of the lysates was determined using a Bio-Rad protein assay (BioRad, Laboratories Inc.; Hercules, CA, USA). The lysates were diluted in 5× sodium dodecyl sulfate (SDS) loading buffer, boiled for 5 min, separated on SDS-polyacrylamide gel electrophoresis gels and transferred to nitrocellulose membranes, which were probed with antibodies (anti-FoxM1 antibody was purchased from R&D Systems; Minneapolis, MN, USA; anti-Bcl-2, -Bax, -p-cJun NH2-terminal kinase (JNK), -JNK, -β-actin, and -GAPDH were purchased from Cell Signaling Technology, Inc.; Danvers, MA, USA), visualized using an ECL reagent, and detected and analyzed using the Bio-Rad Gel Doc XR System.
Transfection of small interfering RNA (siRNA). siRNA that was directed against human FoxM1 (FoxM1-siRNA) and a non-targeting negative control siRNA (NC-siRNA) were purchased from Dharmacon (Denver, CO, USA). The target sequences of the selected siRNA oligonucleotides were as follows: P1, 5΄-CCAACAAUGCUAAUAU-UCA-3΄; P2, 5΄-CAUUGGACCAGGUGUUUAA-3΄; 3, 5΄-GCGCACGGCGGAAGAUGAA-3΄; and 4, 5΄-UGAAA-GACAUCUAUACGUG-3΄. A549/CDDP cells were plated into the wells of a 6-well plate at 1.0 × 10 6 cells per well in 2 mL of 10% fetal bovine serum-supplemented Dulbecco's modified Eagle medium on the day before transfection. After 24 h of incubation, A549/CDDP cells were transfected with FoxM1-siRNA or NC-siRNA duplexes. The transfection procedures were performed following the FuGENE HD transfection reagent manufacturer's protocol (Roche Applied Science; Indianapolis, MN, USA). After 12 h, the transfection efficiency was determined using fluorescence microscopy of A549/CDDP cells that were transfected with FAM-labeled negative control siRNA duplexes. The silencing effect was assayed by quantitative real-time PCR and western blot analysis, 2 d post-transfection. Construction and transfection of the eukaryotic expression vector FoxM1b-pcDNA3.1 (+). The overexpression plasmids and dominant-negative FoxM1 (a loss-of-function mutant of FoxM1; negative control) were purchased from Generay Company (Shanghai, China). The transfected cells were seeded to a confluency of 50% and incubated for 6 h with a mastermix of transfection reagents that contained Fugene-6 (Qiagen; Hilden, Germany) and the plasmids, which were diluted at a ratio of 3:1 in Opti-MEM. Fresh medium was added to replace the transfection reagent, and the cells were allowed to grow overnight. The transfection effect was assayed by quantitative real-time PCR and western blot analysis, 2 d post-transfection.
Statistical analysis. The data are expressed as the mean ± standard deviation (SD). A statistical analysis was performed using SPSS (Statistical Package for the Social Sciences) software (Release 17.0, SPSS, Inc.; Chicago, IL, USA). Associations between FoxM1 expression and clinicopathological characteristics (Table 1) or therapy lines (Table 2) were analyzed using the χ 2 test. The relationships between FoxM1 protein expression and treatment responses (Table 4) were also analyzed using the χ 2 test. Survival probability analyses were performed using the Kaplan-Meier method. The significance of the group differences was assessed by the log-rank test. Multivariate analyses were performed using a logistic regression model for response and Cox regression models for progression-free survival (PFS) and overall survival (OS). The differences between the two groups were analyzed by the Student's t-test or one-way analysis of variance (ANOVA). A value of P < 0.05 was considered to be statistically significant.
Results
FoxM1 expression in advanced NSCLC patients correlated with response to cisplatin-based chemotherapy and survival. We investigated the expression of FoxM1 in 50 unresectable stage III-IV NSCLC tissue samples using an immunohistochemical assay. The cohort included 20 female patients and 30 male patients who were 36-79 years of age (median age = 55 years). The mean follow-up period after diagnosis was 25.0 months. The specimens originated from percutaneous lung biopsy (21 cases), transbronchial lung biopsy (11 cases), lymph node biopsy (13 cases), and palliative surgery (5 cases). The histological classification was based on the 2004 World Health Organization criteria. No chemotherapy or radiotherapy was given to the patients before biopsy.
FoxM1 staining was mainly located in the nucleus. Of the patients who were treated with a cisplatin-based regimen as first-line therapy, 56.0% (28/50) had a tumor with low FoxM1 expression (Fig. 1A) , whereas the remaining patients exhibited high FoxM1 expression (Fig. 1B) , which included both differentiated (Fig. 1C) and undifferentiated (Fig. 1D) lung tumor samples. The correlation between the immunohistochemical staining patterns and the clinical and pathological factors was examined (Table 1 ). The results indicated that there was no significant difference between FoxM1 levels and sex, age, histological type, degree of differentiation, and clinical stage (P > 0.05). Table 2 shows a summary of the first-line treatments and the use of erlotinib or gefitinib as a subsequent treatment. Gemcitabine-cisplatin was the most commonly selected firstline therapy. The high and low FoxM1 expression groups did not vary significantly according to the first-line regimens and the use of tyrosine kinase inhibitors. The epidermal growth factor receptor status was not assessed.
The disease control rate (DCR) after cisplatin-based therapy for all patients was 66.0% (17 partial responses, 16 patients presented a stable disease, and 17 patients presented a progressive disease, Table 3 ). The patients with a low expression of FoxM1 Table 4 ). The overall PFS was 5.0 months (range = 1.0-10.0 months), and the OS was 12.0 months (range = 3.0-21.0 months). The PFS for patients with a low expression of FoxM1 was 5.5 months compared with 4.5 months for patients with a high expression of FoxM1 (P = 0.006, Fig. 2A ). In addition, a better OS was observed in patients with a low expression of FoxM1 (P = 0.031, Fig. 2B ). The univariate analysis indicated that tumor stage and FoxM1 protein expression were important factors that affected OS (Table 5 ). These parameters were prognostic factors for OS in the multivariate analysis using the Cox regression model (Table 6) .
FoxM1 expression in cisplatin-resistant A549 cells. To verify the role of FoxM1 in cisplatin resistance, we investigated the difference between the expression of FoxM1 in A549 and A549/CDDP cells. We established cisplatin-resistant A549/ CDDP cells from A549 human lung cancer cells by stepwise exposure to increasing concentrations of cisplatin. As shown in Figure 3A , the IC50 concentration of A549/CDDP cells was 9.33-fold higher than that of A549 cells (135.21 μmol/L versus 14.49 μmol/L) when the cells were treated with cisplatin. Subsequent real-time quantitative PCR revealed that the FoxM1 mRNA level was on average 7.1-fold higher in A549/CDDP cells compared with parental A549 cells (Fig. 3B) . The results of the western blot analysis were in accordance with those of the real-time quantitative PCR (Fig. 3C) .
Downregulation of FoxM1 by RNA interference sensitizes cisplatin-resistant A549 cells to apoptosis induced by cisplatin. In this study, the RNA interference technique was employed to knockdown FoxM1 expression in A549/CDDP cells. As shown in Figure 4A , the transfection efficiency of A549/CDDP cells that were transfected with FAM-labeled negative control siRNA duplexes was more than 80%, as determined by fluorescence microscopy. The expression of FoxM1 mRNA and protein was significantly more suppressed in A549/CDDP-FoxM1-siRNA cells than in A549/ CDDP-NC-siRNA or A549 non-transfected cells according to the real-time quantitative PCR and western blot results (Fig. 4B, C) , which suggested that RNA interference could effectively inhibit FoxM1 expression in A549/CDDP cells. A cytotoxicity analysis using CCK-8 was performed to detect cell proliferation in the presence of various concentrations of cisplatin. The results demonstrated the sensitivity of A549/ CDDP-FoxM1-siRNA cells to the cisplatin treatment with a 76.4% decrease in the IC50 compared with that of control cells (Fig. 4D) .
Overexpression of FoxM1 using the eukaryotic expression vector FoxM1b-pcDNA3.1(+) decreased the sensitivity of A549 cells to cisplatin. To determine whether FoxM1 is important in cisplatin resistance, we constructed the eukaryotic expression vector FoxM1b-pcDNA3.1(+) and transfected the vector into A549 cells. The real-time quantitative PCR and western blot results showed that the expression of FoxM1 mRNA and protein was significantly more elevated in FoxM1b-pcDNA3.1(+)-A549 cells than in dominantnegative A549 cells or in A549 non-transfected cells (Fig.  5A, B) , which suggested that transfection of the eukaryotic expression vector FoxM1b-pcDNA3.1(+) could effectively increase FoxM1 expression in A549 cells. The proliferation rates were evaluated using CCK-8 and showed that the IC50 in the FoxM1b-pcDNA3.1(+)-A549 cells increased 313% more than in the control groups (Fig. 5C ), which suggested that the overexpression of FoxM1 decreased the sensitivity of A549 cells to cisplatin.
Downregulation of FoxM1 enhanced cisplatin-induced A549/CDDP cell apoptosis through upregulation of JNK phosphorylated level. We hypothesized that the mitochondrial pathway could be involved in the cisplatin-induced A549/ CDDP-FoxM1-siRNA cell apoptosis. To test this hypothesis, three types of cells (non-transfected A549/CDDP, A549/ CDDP-FoxM1-siRNA, and A549/CDDP-NC-siRNA) were treated with cisplatin (20 μmol/L) or cisplatin (20 μmol/L) combined with SP600125 (10 μmol/L), a specific inhibitor of JNKs, for 12 h. Next, the cell viability was analyzed using CCK-8 assays. JNK, p-JNK, Bcl-2, and Bax were further assessed by western blot analysis. The results (Fig. 6 ) revealed that JNK was significantly phosphorylated in the A549/CDDP-FoxM1-siRNA cells that were treated with cisplatin. In addition, the expression of Bcl-2 was reduced, whereas the expression of Bax was enhanced and accompanied by increased cell apoptosis. When SP600125 was used, the western blot demonstrated that the activation of JNK and the apoptosis pathway were inhibited, and cisplatin-induced apoptosis in A549/CDDPFoxM1-siRNA cells decreased.
Discussion
Cisplatin is widely used for the treatment of non-small cell lung cancer. However, chemoresistance remains a major therapeutic problem. The precise molecular mechanisms of cisplatin resistance are not fully understood. Based on our data, low expression rate of FoxM1 in NSCLC was associated with increased chemosensitivity to cisplatin. There was a significant negative relationship between high expression of FoxM1 and survival time. Cox multivariate analysis demonstrated that FoxM1 expression was an independent factor of poor prognosis. When the expression level of FoxM1 was downregulated and upregulated, sensitivity to cisplatin was respectively enhanced and reduced in both A549 and A549/ CDDP cells. FoxM1 downregulation enhanced cisplatin- induced A549/CDDP cell apoptosis through activation of the JNK/mitochondrial pathway. These results suggest that FoxM1 plays a critical role in chemoresistance to cisplatin and FoxM1 depletion may be a promising approach to improve lung cancer therapy.
Cisplatin is a platinum-based compound that forms intraand inter-strand adducts with DNA. These adducts distort the DNA conformation and inhibit replication and transcription, leading to the activation of multiple signaling pathways involved in the cell cycle and apoptosis [4] . Previous studies have reported that the main molecular mechanisms of chemoresistance involve the activation of cell cycle pathways, increased DNA damage repair, and alterations in apoptosis regulator genes [29] . Two major signaling pathways that lead to apoptosis have previously been described [30] . One pathway involves death receptors and tumor necrosis factor receptors (TNFRs), whereas the other pathway is the mitochondrial pathway that involves the Bcl-2 and Bax proteins. Bcl-2 is well known as an anti-apoptotic mediator, and the overexpression of Bcl-2 can inhibit cell apoptosis that is induced by free radicals, radiation, steroid hormones, chemotherapy, and oncogenes. The proapoptotic protein Bax can promote the release of cytochrome c into the cytosol from mitochondria that activates caspases that are involved in apoptosis [30] .
In this study, we first observed the FoxM1 expression status in 50 unresectable stage III-IV NSCLC patients who were treated with a cisplatin-based regimen as first-line therapy. We did not find a significant relationship between the FoxM1 expression level and the histological grade or the clinical stage that represented the clinical course of the disease. This finding may be attributed to the small number of samples and the late clinical stage of these patients. For further verification, the sample size will be increased. When we analyzed the outcome, we found that FoxM1 was a negative factor that was associated with sensitivity to cisplatin and a shorter survival time. Thus, FoxM1 could be a useful marker for predicting and monitoring responses to cisplatin and prognoses in NSCLC patients.
It has been previously reported that FoxM1 is a proliferation-specific transcription factor [31] . FoxM1 promotes G1/S transition and tumor cell invasiveness through mitogenactivated protein kinases (MAPKs) [32] . MAPKs are serine/ threonine kinases that transduce signals from the cell membrane to the nucleus in response to a wide range of stimuli [33, 34] . The MAPK signaling pathways modulate gene expression, mitosis, proliferation, motility, metabolism, and programmed cell death (i.e., apoptosis) [35] [36] [37] . There are three family members of the conventional MAPKs: the extracellular signalregulated kinase (ERK), JNK, and p38-MAPK [38] . Recent evidence suggests that the activity of the Raf/MEK/MAPK is necessary and sufficient for the nuclear translocation of FoxM1 [39] . Moreover, FoxM1 has been identified downstream of Ras-MKK3-p38 in the regulation of in vitro cellular invasion [40] . JNK plays a major role in cisplatin-induced cancer cell apoptosis [41, 42] . However, the relationship between FoxM1 and the JNK pathway in cancer resistance has not been reported. Wang et al. reported that FoxM1 acts as an upstream regulator of the JNK1 signaling pathway to promote the G1/S transition and tumor cell invasiveness. They demonstrated that FoxM1 directly binds and activates the JNK1 promoter [32] . Based on previous studies, we hypothesized that FoxM1 mediated sensitivity to cisplatin in A549 cells via the JNK/ mitochondrial pathway.
To test this hypothesis, we silenced FoxM1 expression in A549/CDDP cells and treated the cells using cisplatin with or without a specific inhibitor of JNK. We found that when the expression of FoxM1 was downregulated, p-JNK level was increased and accompanied by an enhanced sensitivity to cisplatin. Previous studies have verified that p-JNK expression is an indirect measure of JNK activation [43] . The balance of Bcl-2/Bax expression is an important mark of the apoptosis signaling pathway. The results suggested that JNK was an apoptotic signal that was activated by the silencing of FoxM1. Interestingly, the blockade of JNK with SP600125 significantly reversed the activation of the mitochondrial pathway, inhibited the cell apoptosis pathway, and the sensitivity of the A549/ CDDP-siFoxM1 cells to cisplatin was reduced. These results suggested that the JNK pathway is an essential signaling pathway that participates in the regulation of FoxM1 in cisplatin resistance. However, the mechanism of drug resistance in tumors is complicated and involves multiple signaling pathways. Therefore, multiple genes, including FoxM1, may interact with each other and form an intricate network. Remarkably, many of the target genes of FoxM1, such as p53 and polo-like kinase 1 (PLK1), are associated with multidrug resistance. Evidence suggests that ATM and p53 coordinately regulated FoxM1 to modulate responses and resistance to epirubicin in breast cancer [19] . It has been shown that PLK1 plays a role in DNA damage recognition with homologous recombination repair and has been involved in multidrug resistance [44] [45] [46] . Based on the interaction between FoxM1 and its downstream genes, FoxM1 could be used as a therapeutic target to overcome acquired resistance to chemotherapy.
This study has several limitations. First, we only focused on one cell line, A549, which is a widely used human lung adenocarcinoma cell line. Additional observations in other cell lines may strengthen the significance of our study. Second, we explored one signaling pathway, the JNK pathway, and there may be other FoxM1 target genes and pathways that are associated with multidrug resistance. However, these limitations did not influence the conclusion of our study. Third, we only investigated the JNK phosphorylation level. The mechanisms of how FoxM1 regulates the JNK pathway still remain unclear. Additional efforts will contribute to our understanding of the precise underlying mechanisms explaining how FoxM1 suppression enhances lung cancer cell sensitivity to cisplatin.
In summary, based on our experiments, FoxM1 is a critical mediator of cisplatin sensitivity in NSCLC. The downregulation of FoxM1 enhanced cisplatin-induced A549/CDDP cell apoptosis through activation of the JNK/mitochondrial pathway. Therefore, a combination of cisplatin treatment with FoxM1 depletion may be an effective approach to lung cancer therapy.
